CA3137240A1 - Method of treatment - Google Patents

Method of treatment Download PDF

Info

Publication number
CA3137240A1
CA3137240A1 CA3137240A CA3137240A CA3137240A1 CA 3137240 A1 CA3137240 A1 CA 3137240A1 CA 3137240 A CA3137240 A CA 3137240A CA 3137240 A CA3137240 A CA 3137240A CA 3137240 A1 CA3137240 A1 CA 3137240A1
Authority
CA
Canada
Prior art keywords
agent
seq
protein
nomacopan
replaced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3137240A
Other languages
English (en)
French (fr)
Inventor
Wynne H Weston-Davies
Virginia CALDER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Volution Immuno Pharmaceuticals SA
Original Assignee
Volution Immuno Pharmaceuticals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Volution Immuno Pharmaceuticals SA filed Critical Volution Immuno Pharmaceuticals SA
Publication of CA3137240A1 publication Critical patent/CA3137240A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CA3137240A 2019-04-25 2020-03-04 Method of treatment Pending CA3137240A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1905810.6A GB201905810D0 (en) 2019-04-25 2019-04-25 Method of treatment
GB1905810.6 2019-04-25
GBGB2000955.1A GB202000955D0 (en) 2019-04-25 2020-01-22 Method of treatment
GB2000955.1 2020-01-22
PCT/EP2020/055741 WO2020216513A1 (en) 2019-04-25 2020-03-04 Method of treatment

Publications (1)

Publication Number Publication Date
CA3137240A1 true CA3137240A1 (en) 2020-10-29

Family

ID=66810336

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3137240A Pending CA3137240A1 (en) 2019-04-25 2020-03-04 Method of treatment

Country Status (10)

Country Link
US (1) US20220211810A1 (cg-RX-API-DMAC7.html)
EP (1) EP3958974A1 (cg-RX-API-DMAC7.html)
JP (1) JP7603612B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220018963A (cg-RX-API-DMAC7.html)
CN (1) CN114072206B (cg-RX-API-DMAC7.html)
AU (1) AU2020263709A1 (cg-RX-API-DMAC7.html)
CA (1) CA3137240A1 (cg-RX-API-DMAC7.html)
GB (2) GB201905810D0 (cg-RX-API-DMAC7.html)
IL (1) IL287250A (cg-RX-API-DMAC7.html)
WO (1) WO2020216513A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202218084D0 (en) * 2022-12-01 2023-01-18 Volution Immuno Pharmaceuticals Sa Fusion proteins
WO2024238859A1 (en) * 2023-05-16 2024-11-21 Regenxbio Inc. Vectorized c5 inhibitor agents and administration thereof
GB202408081D0 (en) 2024-06-06 2024-07-24 Volution Immuno Pharmaceuticals Sa Methods of removing impurities

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7884188B2 (en) 2003-06-02 2011-02-08 Varleigh Immuno Pharmaceuticals (Vip) Ltd Complement inhibitors
GB0518443D0 (en) 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
GB0617734D0 (en) 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
EP2061501B1 (en) 2006-09-08 2015-04-08 Volution Immuno Pharmaceuticals SA Method of treating respiratory disorders
WO2008113834A2 (en) 2007-03-22 2008-09-25 Novartis Ag C5 antigens and uses thereof
US8563521B2 (en) * 2007-06-21 2013-10-22 Technische Universitat Munchen Biological active proteins having increased in vivo and/or in vitro stability
GB0802116D0 (en) * 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
GB0906779D0 (en) * 2009-04-20 2009-06-03 Natural Environment Res Council Composition
CA2785612C (en) * 2010-01-08 2019-09-10 Varleigh Immuno Pharmaceuticals (Vip) Ltd. Ev576 for use in the treatment of viral infections of the respiratory tract
GB201401453D0 (en) * 2014-01-28 2014-03-12 Univ Birmingham Transmucosal and transepithelial drug delivery system
GB201410116D0 (en) * 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
WO2016198133A1 (en) 2015-06-08 2016-12-15 Volution Immuno Pharmaceuticals Sa Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease
EP3359566A1 (en) 2015-10-07 2018-08-15 Alexion Pharmaceuticals, Inc. A method for treating age-related macular degeneration in a patient
MX2018016046A (es) * 2016-06-27 2019-05-02 Achillion Pharmaceuticals Inc Quinazolina y compuestos indol para tratar trastornos medicos.
EP3570888A1 (en) * 2017-03-03 2019-11-27 MacRegen, Inc. Treatment of age-related macular degeneration and other eye diseases with one or more therapeutic agents
JP7209637B2 (ja) * 2017-04-21 2023-01-20 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 自己免疫性水疱症の治療のためのコバーシン
GB201706406D0 (en) * 2017-04-21 2017-06-07 Volution Immuno Pharmaceuticals Sa Method of treatment
CN110831617A (zh) * 2017-04-21 2020-02-21 沃卢申伊缪诺制药公司 用于治疗瘢痕性眼部发炎性病症的Coversin
JP7629394B2 (ja) * 2018-09-10 2025-02-13 ヴォリューション イミュノ ファーマシューティカルズ エスエイ リウマチ性疾患の治療に使用するためのコバーシン
JP2023503776A (ja) * 2019-09-27 2023-02-01 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 造血幹細胞移植後の血栓性微小血管症(hsct-tma)の治療方法

Also Published As

Publication number Publication date
US20220211810A1 (en) 2022-07-07
KR20220018963A (ko) 2022-02-15
EP3958974A1 (en) 2022-03-02
CN114072206B (zh) 2024-11-08
GB201905810D0 (en) 2019-06-05
GB202000955D0 (en) 2020-03-04
AU2020263709A1 (en) 2021-12-23
JP7603612B2 (ja) 2024-12-20
WO2020216513A1 (en) 2020-10-29
JP2022530068A (ja) 2022-06-27
IL287250A (en) 2021-12-01
CN114072206A (zh) 2022-02-18

Similar Documents

Publication Publication Date Title
Mesquida et al. The role of inflammation in diabetic eye disease
CN110896606B (zh) 用于治疗自身免疫性水疱病的coversin
JP2018535696A (ja) 遺伝子構築物
US20220211810A1 (en) Method of Treatment
CN105007931A (zh) 肽在视网膜神经退行性疾病,特别是在糖尿病视网膜病变早期和神经退行性变起重要作用的其它视网膜疾病的局部治疗中的应用
JP2018514590A (ja) ペプチド組成物および使用方法
JP2024167222A (ja) 加齢黄斑変性の治療における融合タンパク質の使用
CA2666843C (en) Treatment of age-related macular degeneration and other diseases of the eye
CN113645994A (zh) 使用色素上皮衍生因子(pedf)治疗疾病的方法
JP7068706B2 (ja) 網膜神経変性疾患の眼局所治療のためのジペプチジルペプチダーゼ-4阻害剤
CA3153803A1 (en) Method of treatment of hematopoietic stem cell transplant associated thrombotic microangiopathy (hsct-tma)
WO2019043649A2 (en) ANGIO -3 FOR THE TREATMENT OF RETINAL ANGIOGENIC DISEASES
JP2024038469A (ja) インフラマソームの活性化を阻害するためのcd59
WO2013005603A9 (ja) 結膜におけるアレルギー性炎症の予防及び/又は治療剤
WO2025036488A9 (en) Methods of treating age-related macular degeneration and diabetic macular edema
CN107041949A (zh) 在cns神经性损伤后非‑急性期间处理的组合物及方法
US10232019B2 (en) Method of treating hyperglycemic disorders using apolipoprotein AIV
Zhang et al. Cytokines in age-related eye diseases: Pathogenesis and potential targets for innovative therapies
KR20220051791A (ko) Fas 신호전달 억제용 펩타이드를 포함하는 황반변성 예방 또는 치료용 조성물
WO2024115767A1 (en) Nomacopan-pas fusion proteins
AU2012314330B2 (en) Compositions and methods for the treatment of degenerative retinal conditions
Dabouz Neuro-immune interactions in age-related macular degeneration: implications for future therapeutics
CN110072543A (zh) 脑梗塞的治疗药

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240228

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241220

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241220

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241220

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250821

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251211

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251211

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20251222

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260708